Diabetes Clinical Trials in Illinois

Showing 481-500 of 608 trials

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

NCT00071409

Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to restore the ability to produce insulin in type 1 diabetic patients.

Diabetes Mellitus, Insulin-Dependent

Exsulin Corporation63 participantsStarted Oct 2003

Irvine, California, United States • San Diego, California, United States • Walnut Creek, California, United States +7 more locations

COMPLETEDPhase 2111 miles

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

NCT01376557

This study is intended to assess the effect on HbA1c of different dose regimens of LX4211 in combination with metformin in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin monotherapy.

Type 2 Diabetes Mellitus

Lexicon Pharmaceuticals299 participantsStarted Jun 2011

Anaheim, California, United States • Carmichael, California, United States • Greenbrae, California, United States +53 more locations

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Diabetes Trials in Other Cities

The CareFUL Prevention Trial

Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

Weight Loss Study for People With Type 2 Diabetes

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

Study of A Cell-Phone System to Improve Health of Youth With Diabetes

Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Other Conditions in Illinois